Which treatments have been shown to be effective in randomized clinical trials (RCTs) for hidradenitis suppurativa (HS) in adults?
There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, −3.7 to −2.0 points) and 1.6 points (95% CI, −3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.
Ingram JR. Interventions for Hidradenitis Suppurativa: Updated Summary of an Original Cochrane Review. JAMA Dermatol. 2017;153(5):458–459. doi:10.1001/jamadermatol.2017.0432
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: